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Global rateAbstract In medicine, the relationship between erythropoietin and heart disease is sometimes
mentioned. An attempt to demonstrate connection between erythropoietin and heart failure is
very interesting. The attempt is based on the interrelationship among erythropoietin disturbance,
anemia and heart disorder. However, the factors that can affect the endemic pattern must be
considered.
ª 2012 Tehran University of Medical Sciences. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.Erythropoietin is an important hormone secreted from the
kidney [1]. This hormone is necessary for the normal erythro-
poiesis process [1]. Abnormalities of erythropoietin can be
observed in many diseases including haematological disorders
and renal diseases. In cardiology, the relationship between
erythropoietin and heart disease is sometimes mentioned.
Most publications usually mention for anaemia and cardiovas-
cular disease. It is no doubt that erythropoietin and anaemia
have a strong interrelationship [2]. Hence, a transferring
interrelationship between erythropoietin and complication of
anaemia can be expected. The cardiac consequence of severe
anaemia can be observed and this is an important, little-
mentioned topic in cardiology [3]. In chronic anaemia,
left-ventricular hypertrophy and poor coronary blood
perfusion can be observed [3]. Of interest, a recent report indi-
cated that four-tenths of all hospitalized patients with heartniversity of Medical Sciences. Pub
h/
/j.jmhi.2012.10.003failure had the problem of ‘anaemia’ [4]. The usefulness of
erythropoietin as a biomarker in heart disease has been pro-
posed for a few years [5]. Further, the use of erythropoietin
for treatment is a new concept in cardiology [5]. At present,
it is accepted that erythropoietin is a biomolecule with haema-
topoietic and pleiotropic effects [6]. Used as a laboratory
biomarker, erythropoietin is widely studied for its usefulness
in heath failure. George et al. proposed that ‘‘determination
of circulating EPO levels may aid in predicting morbidity
and mortality in patients with clinically controlled congestive
CHF’’ [7]. Nevertheless, it is surprisingly found that erythro-
poietin relates poorly to hemoglobin level despite the good
prognostic value of erythropoietin in patients with heart failure
being observed [8].
A recent publication in our journal is an attempt to demon-
strate the connection between erythropoietin and heart failurelished by Elsevier Ltd. Open access under CC BY-NC-ND license.
6 V. Wiwanitkit[9]. The hypothesis made by Ismailov is very interesting.
Linking the prevalence of heart failure and observed
erythropoietin level based on geographical parameters might
be too far-fetched, but it can be imagined. In fact, Ismailov
also published another paper in another journal on the
relationship between erythropoietin and coronary heart dis-
ease with the same style of hypothesis [10]. An important fact
to be considered is there are many factors that can affect
erythropoietin. Some diseases such as thalassemia that can
be seen in an endemic pattern in some areas can seriously alter
the pattern of erythropoietin without any relationship to
geography.
Nevertheless, the explanation regarding the difference of
the determined rate of heart diseases in different settings and
the possible relationship to difference in erythropoietin levels
seems a challenge. As previously mentioned, one might argue
that there can be other factors that can affect the ﬁnal rates.
However, this idea can be the starting point for future studies
in this area. At least, an interesting focus can be the study on
the genetics underlying erythropoietin and heart disease
among different populations.
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